| Patient | Irène Joliot-Curie |
|---|---|
| Date of birth | 1897-09-12 |
| Identifiers | MRN HR-RB003-SYN-TD; SSN (made up) 000-03-8841 |
| Document date | 1955-10-30 |
| Author | Solène Marchand-Ellis, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Count recovery, response assessment, cycle 2, transplant planning, and her dose records. [S]
Mrs. Joliot-Curie returns on day 33, eleven days after venetoclax was stopped. She feels stronger, walks for half an hour, and has begun reading papers again. She has had no fever or bleeding. Her posaconazole trough level, drawn three days ago, was in the target range. The transplant center reports that the unrelated donor search has found two fully matched donors. Her employer's radiation safety office has acknowledged her request and is assembling her dose records, including the bioassay from the laboratory accident. [S]
| Element | Detail |
|---|---|
| Cycle | Day 33 of cycle 1; venetoclax stopped on day 22 |
| Symptoms | Stronger; no fever or bleeding |
| Transplant | Two fully matched unrelated donors identified |
| Dose records | Request acknowledged; records being assembled |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; no fever or night sweats |
| Respiratory | Positive | Breathless on stairs, as before |
| Gastrointestinal | Negative | Eating well; bowels regular |
| Integumentary | Negative | No bruises |
| Psychiatric | Negative | Mood steady; PHQ-9 6 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycle | Once daily on days 1 to 7 of each 28-day cycle | Subcutaneous route | 1955-09-28 | active | S |
| Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole) | Ramp-up, then two tablets daily with the 50 mg tablet, with food and water | Oral route | 1955-09-28 to 1955-10-19 | completed | S |
| Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day) | One tablet daily from day 3, with food and water | Oral route | 1955-09-28 to 1955-10-19 | completed | S |
| Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic | 300 mg twice on day 1, then 300 mg once daily with food | Oral route | 1955-09-28 | active | S |
| Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxis | One tablet twice daily | Oral route | 1955-09-28 | active | S |
| Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5 | One tablet daily during profound neutropenia | Oral route | 1955-09-28 to 1955-10-30 | completed | S |
| Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1 | One tablet daily | Oral route | 1955-09-28 to 1955-10-19 | completed | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nausea | One tablet every 8 hours as needed | Oral route | 1955-10-08 | active | S |
| Polyethylene glycol 3350, 17 g powder in a glass of water once daily | 17 g once daily, held for loose stools | Oral route | 1955-10-08 | active | S |
| Sennosides 8.6 mg oral tablet, two tablets at bedtime | Two tablets at bedtime | Oral route | 1955-10-08 to 1955-10-19 | completed | S |
| Potassium chloride 20 mEq extended-release tablet, one tablet twice daily for three days | One tablet twice daily for three days | Oral route | 1955-10-08 to 1955-10-11 | completed | S |
| Venetoclax 10 mg oral tablet, cycle 2: two tablets daily with the 50 mg tablet (70 mg a day, the dose with posaconazole) on days 1 to 21 | Two tablets daily on days 1 to 21, with food and water | Oral route | 1955-10-30 | active | S |
| Venetoclax 50 mg oral tablet, cycle 2: one tablet daily with two 10 mg tablets (70 mg a day) on days 1 to 21 | One tablet daily on days 1 to 21, with food and water | Oral route | 1955-10-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1955-10-30 | Body height | 163 | cm | S |
| 1955-10-30 | Body weight | 53.6 | kg | S |
| 1955-10-30 | Body mass index (BMI) [Ratio] | 20.2 | kg/m2 | S |
| 1955-10-30 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1955-10-30 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1955-10-30 | Heart rate | 84 | /min | S |
| 1955-10-30 | Respiratory rate | 16 | /min | S |
| 1955-10-30 | Body temperature | 36.8 | Cel | S |
| 1955-10-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1955-10-30 | Leukocytes [#/volume] in Blood by Automated count | 2.2 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1955-10-30 | Neutrophils [#/volume] in Blood by Automated count | 0.9 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 1955-10-30 | Hemoglobin [Mass/volume] in Blood | 9.6 | g/dL | 12-15.5 g/dL | Low | S |
| 1955-10-30 | Platelets [#/volume] in Blood by Automated count | 88 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1955-10-30 | Blasts/Leukocytes in Blood by Manual count | 0 | % | None seen normally | Normal | S |
| 1955-10-30 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1955-10-30 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1955-10-30 | Creatinine [Mass/volume] in Serum or Plasma | 0.81 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 1955-10-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1955-10-30 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-35 U/L | Normal | S |
| 1955-10-30 | ECOG Performance Status score | 1 | {score} | S | ||
| 1955-10-30 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
Vital signs recorded on 1955-10-30; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Brighter; weight 53.6 kg; ECOG 1 |
| Mouth | No ulcers or thrush |
| Respiratory | Fine crackles at the right apex, unchanged |
| Skin | No bruises or petechiae |
| Abdomen | No enlarged liver or spleen |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Two months of tiredness, easy bruising and bleeding gums, with pancytopenia and 12 percent blasts on the blood smear; acute leukemia suspected and urgent hematology review booked | resolved | confirmed | D61.818 | S — Synthetic presenting concern at the index visit, superseded by the bone marrow diagnosis two days later; its timing echoes the documented decline in her health (D). |
| Acute myeloid leukemia diagnosed on bone marrow biopsy (34 percent myeloblasts), in a physicist with decades of occupational exposure to ionizing radiation; synthetic modern diagnosis linked to her documented leukemia | active | confirmed | C92.00 | S — Synthetic modern diagnosis and subtype; the type of her real leukemia is not documented. |
| Occupational exposure to ionizing radiation over about four decades: X-ray work early in her career, laboratory work with polonium and other radioactive sources, and a laboratory accident in which a sealed polonium source ruptured on her bench about ten years ago | active | confirmed | Z57.1 | S — Synthetic modern coding of her documented occupational exposure. |
| Pulmonary tuberculosis in her forties, treated to completion; no symptoms of active disease | active | confirmed | Z86.11 | S — Synthetic modern coding of her documented tuberculosis; the treatment details are synthetic. |
| Moderately reduced lung gas transfer (DLCO 58 percent of predicted, FEV1 76 percent) from old tuberculous scarring of the right upper lobe; with performance status 2, it makes her unfit for intensive induction | active | confirmed | R94.2 | S — Synthetic finding on pre-treatment testing. |
| Nausea with vomiting and constipation on day 11 of cycle 1 of azacitidine with venetoclax, without fever, with mild low potassium; managed as an outpatient; resolved | resolved | confirmed | R11.2 | S — Synthetic treatment side effect; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with differential and smear | At diagnosis; two to three times a week during induction; before each cycle | Completed today | White cells 2.2, neutrophils 0.9, hemoglobin 9.6 g/dL, platelets 88 x10^3/uL; no blasts: ELN 1951 complete remission with partial hematologic recovery |
| Laboratory | Bone marrow: morphology, flow cytometry, cytogenetics, molecular panel | At diagnosis; day 21 to 28 of cycle 1; then as response and transplant planning require | Due | Measurable residual disease marrow after cycle 2 |
| Laboratory | Chemistry: electrolytes, creatinine, calcium, phosphate, uric acid, LDH, liver tests | At diagnosis; during venetoclax ramp-up for tumor lysis; then weekly in cycle 1 and before each cycle | Completed today | Sodium 139, potassium 4.2 mmol/L; creatinine 0.81 mg/dL, eGFR 84; ALT 28 U/L |
| Medication safety | Azole safety: posaconazole interactions (venetoclax dose), liver tests, QTc, trough level | At start; liver tests weekly; trough level after about a week of dosing; QTc with any added QT-prolonging drug | Completed today | Trough level in the target range three days ago; liver tests normal; venetoclax kept at 70 mg |
| Survey | Performance status | Before each cycle | Completed today | ECOG 1, from 2 at the start of treatment |
| Medication safety | Transfusion support: thresholds, irradiated and leukoreduced products | At each blood count | Completed today | No transfusion needed since day 11 |
| Self-management | Infection prophylaxis and the fever plan | Throughout neutropenia | Completed today | Levofloxacin stopped; posaconazole and acyclovir continue through cycle 2; fever plan unchanged |
| Referral | HLA typing and allogeneic transplant evaluation | During remission | Completed today | Two matched unrelated donors found; reduced-intensity transplant planned after two to three more cycles |
| Referral | Specialist palliative care: symptoms, prognosis, goals and values | At every visit | Completed today | Palliative care continues alongside treatment; goals recorded at the preventive visit |
| Survey | Distress, depression and anxiety screening | At each phase of treatment | Completed today | PHQ-9 6, mild |
| Self-management | Occupational exposure history and dose records | Until the records are received | Due | Request acknowledged; records being assembled |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022); DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (VIALE-A). N Engl J Med 2020 (PMID 32786187) (2020); NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026); Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: ASCO and IDSA Clinical Practice Guideline Update (PMID 29461916) (2018); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024 (PMID 38748941) (2024); Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023); Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015); 10 CFR 19.13, Notifications and reports to individuals (radiation exposure reports on request) (2026); 29 CFR 1910.1096, Ionizing radiation (records of exposure and disclosure to employees) (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Cycle 2 as planned, with twice-weekly blood counts. Marrow after cycle 2. Transplant center visit in two weeks. Palliative care at each visit. Emergency department at once for a temperature of 38.0 °C or more. [S]